Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Exp Immunol
Main Authors: Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M., Ueland, T.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591141/
https://ncbi.nlm.nih.gov/pubmed/30821848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13283
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker